The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.

As part of this set of rules, participating pharma companies may have to release the figures, terms and other specifics of deals made regarding products they have developed to fight any future emergencies.

The draft of the WHO accord on this matter is being reviewed and settled between the 194 UN health agency member countries.

The current draft calls for there to be greater transparency in how public funding for the development of vaccines and other medicines is used. It also includes guidelines to ensure the equitable distribution of any manufactured products around the world.

The accord is affectionately known as the pandemic treaty, and hopes to mitigate delays and bureaucratic dilemmas in the face of a new global health emergency, taking what we have learnt from the COVID-19 pandemic and refine our response. With a main aim to ensure less developed and poorer countries are not left to fend for themselves.

In the COVID-19 pandemic, the majority of contracts between pharmaceutical companies and governments were kept private, meaning terms of their agreement and figures were confidential leaving little accountability.

The WHO stated that the new accord, which is still in the beginning stages of formation, would be open to the public and stakeholders for comment before being finalised, leading to amore agreeable way of coordinating efforts in the future.

"The process is open, transparent, and with the input from other stakeholders, including any interested stakeholders and public, able to submit comments at public consultations."

Currently the agreement does not state any specific consequences if countries and companies do not follow the proposed guidelines as the UN agency cannot necessitate that the guidelines are followed to the letter.

The UN agency’s proposed agreement may leave some Big Pharma companies somewhat disgruntled, as they were the ones to step in and develop the vaccines and treatments that were invaluable in curbing the loss of life from the COVID-19 pandemic, with Pfizer and BioNTech, Moderna and AstraZeneca mobilising to launch vaccines less than a year after the start of the pandemic in China in 2019.

Thomas Cueni, Director General for the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), stated that it was an “important milestone” but, "If the draft were implemented as written today it would most likely undermine rather than facilitate our collective ability to rapidly develop and scale up counter measures and ensure its equitable access.”

The guidelines not only set out how best to handle a global health emergency, but also measures in how to recognise them and assess preparedness, with an aim of preventing them.

The accord will have to go through several rounds of review and meetings, the next of which will be held in December, with the finalised treaty not expected to be in place until 2024.

WHO Director-General Tedros Adhanom Ghebreyesus has described the treaty as a once-in-a-generation opportunity to strengthen global health rules by.

https://www.cphi-online.com